Latest1 information on COVID-19
©2022 Stanford Medicine
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Not Recruiting
Trial ID: NCT02654483
Purpose
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and
safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Official Title
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Stanford Investigator(s)
Jean Y. Tang MD PhD
Professor of Dermatology
Albert Sean Chiou, MD, MBA
Clinical Associate Professor, Dermatology
Eligibility
Inclusion Criteria:
- Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria:
- Chronic liver or renal disease
Intervention(s):
drug: VPD-737
drug: VPD-737
other: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claudia Teng
725-7152